Partners Capital Investment Group LLP Lowers Stake in Kronos Bio, Inc. (NASDAQ:KRON)

Partners Capital Investment Group LLP reduced its holdings in shares of Kronos Bio, Inc. (NASDAQ:KRON) by 67.3% in the fourth quarter, HoldingsChannel reports. The fund owned 527,500 shares of the company’s stock after selling 1,084,012 shares during the period. Partners Capital Investment Group LLP’s holdings in Kronos Bio were worth $501,000 as of its most recent SEC filing.

Separately, Peapod Lane Capital LLC purchased a new position in Kronos Bio in the fourth quarter worth about $534,000. Institutional investors and hedge funds own 64.09% of the company’s stock.

Kronos Bio Stock Performance

Shares of KRON stock opened at $1.02 on Monday. The company has a 50 day moving average price of $0.99 and a 200-day moving average price of $0.98. Kronos Bio, Inc. has a 52 week low of $0.69 and a 52 week high of $1.60.

Analyst Ratings Changes

Several research analysts have issued reports on KRON shares. Piper Sandler cut shares of Kronos Bio from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $6.00 to $1.00 in a report on Thursday, November 14th. TD Cowen cut shares of Kronos Bio from a “buy” rating to a “hold” rating in a report on Thursday, November 14th.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.